Patents by Inventor Elaine Todd Sewell

Elaine Todd Sewell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20210095046
    Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.
    Type: Application
    Filed: May 11, 2020
    Publication date: April 1, 2021
    Inventors: John W. BLANKENSHIP, Elaine Todd SEWELL, Philip TAN
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20180100021
    Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific poly-peptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.
    Type: Application
    Filed: September 8, 2017
    Publication date: April 12, 2018
    Inventors: John W. BLANKENSHIP, Elaine Todd SEWELL, Philip TAN
  • COMPOSITIONS AND METHODS FOR COMBINATION THERAPY WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS
    Publication number: 20180022819
    Abstract: The present disclosure relates to combination treatments with anti-androgen therapeutics, including enzalutamide, and prostate-specific membrane antigen (PSMA)-binding polypeptides including multi-specific polypeptide therapeutics that specifically target cells expressing PSMA and are capable of redirecting T-cell cytotoxicity. Such therapeutics are useful for the treatment of prostate cancer (e.g., castration-resistant prostate cancer). In one embodiment, multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides compositions comprising the multi-specific polypeptide therapeutics and one or more anti-androgen therapeutics.
    Type: Application
    Filed: February 11, 2016
    Publication date: January 25, 2018
    Inventors: John BLANKENSHIP, Elaine Todd SEWELL
  • PROSTATE-SPECIFIC MEMBRANE ANTIGEN BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20170306045
    Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.
    Type: Application
    Filed: May 3, 2017
    Publication date: October 26, 2017
    Inventors: John W. BLANKENSHIP, Elaine Todd SEWELL, Philip TAN
  • Prostate-specific membrane antigen binding proteins and related compositions and methods
    Patent number: 9782478
    Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: October 10, 2017
    Assignee: Aptevo Research and Development LLC
    Inventors: John W. Blankenship, Elaine Todd Sewell, Philip Tan
  • Prostate-Specific Membrane Antigen Binding Proteins and Related Compositions and Methods
    Publication number: 20140161800
    Abstract: The present invention relates to mono-specific and multi-specific polypeptide therapeutics that specifically target cells expressing prostate-specific membrane antigen (PSMA) and are useful for the treatment of prostate cancer (e.g., castrate-resistant prostate cancer), tumor-related angiogenesis or benign prostatic hyperplasia (BPH). In one embodiment, the multi-specific polypeptide therapeutics bind both PSMA-expressing cells and the T-cell receptor complex on T cells to induce target-dependent T-cell cytotoxicity, activation and proliferation.
    Type: Application
    Filed: April 20, 2012
    Publication date: June 12, 2014
    Inventors: John W. Blankenship, Elaine Todd Sewell, Philip Tan